Home › Calculator › REGMF Dividend Calculator 2026
REGMF Dividend DRIP Calculator 2026
18.30% YieldHealthcareRemeGen Co., Ltd. · OTC
Price: $10.93 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When REGMF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your REGMF snowball 📈
$10,000 in REGMF → $53.7K in 10 years · $691.89/month
About RemeGen Co., Ltd. (REGMF) — Dividend Analysis 2026
RemeGen Co., Ltd., a biopharmaceutical firm established in Yantai, People's Republic of China, in 2008, focuses on the discovery, development, and commercialization of biologics. The company aims to address unmet medical needs in autoimmune, oncology, and ophthalmic diseases across Mainland China and the United States. Its commercial portfolio includes Telitacicept (RC18), indicated for the autoimmune condition systemic lupus erythematosus, and Disitamab Vedotin (RC48), prescribed for various forms of cancer. RemeGen boasts a robust development pipeline. Telitacicept (RC18) is currently in Phase III clinical trials for neuromyelitis optica spectrum disorder and rheumatoid arthritis, and in Phase II for IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis. Another candidate, RC28, has concluded Phase I trials for ophthalmic indications such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Further assets in Phase I trials include RC98, a PD-L1 monoclonal antibody targeting solid tumors; RC88, being explored for mesothelioma, bile duct carcinoma, pancreatic, ovarian, and lung adenocarcinoma, along with other solid tumors, and lung and urothelial cancers; and RC108, also under investigation for a variety of solid tumors. Beyond clinical stages, RemeGen is advancing several preclinical programs. These comprise RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198, all designed for various solid tumor indications, alongside RC208, RC218, and RC228, which are intended for ophthalmic treatments.
Compare REGMF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full REGMF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open REGMF position with:
🌍 REGMF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold REGMF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 18.30% | 15.50% | $1,830 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 15.55% | 12.75% | $1,556 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 14.64% | 11.84% | $1,464 / yr |
| 🇬🇧 UK ISA | 0% | 18.30% | 15.50% | $1,830 / yr |
| 🇬🇧 UK Taxable | 8.75% | 16.70% | 13.90% | $1,670 / yr |
| 🇨🇦 TFSA | 0% | 18.30% | 15.50% | $1,830 / yr |
| 🇨🇦 CA Taxable | 25% | 13.73% | 10.93% | $1,373 / yr |
| 🇦🇺 Super (pension) | 15% | 15.55% | 12.75% | $1,556 / yr |
| 🇦🇺 AU Taxable | 30% | 12.81% | 10.01% | $1,281 / yr |
| 🇩🇪 DE Taxable | 26.375% | 13.47% | 10.67% | $1,347 / yr |
| 🇫🇷 FR Taxable | 30% | 12.81% | 10.01% | $1,281 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 REGMF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 REGMF Dividend Payment Schedule
REGMF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 REGMF vs Healthcare Benchmarks
How REGMF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for REGMF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ REGMF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the REGMF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
RemeGen Co., Ltd. (REGMF) is currently trading at $10.93, 30% below its 52-week high. The current dividend yield is 18.30% based on an annual payout of $2.00 per share.
REGMF (RemeGen Co., Ltd.) — 18.30% Dividend Yield Analysis
RemeGen Co., Ltd. (REGMF) is a healthcare stock currently trading at $10.93 with a dividend yield of 18.30%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (18.30%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.